LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 6,736,841 ordinary shares at a public offering price of $47.50 per share, which includes 947,368 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary s ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Accessibility StatementSkip Navigation ROCKVILLE, Md., Sept. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced Chief Medical Officer, Steve Pakola, M.D., will present at the International Congress of the World Muscle Society taking place in Vienna, Austria, October 7-11, 2025. The podium presentation will share new analysis of previously presented 12-month functional data from the Phase I/II trial of RGX-202, including individual patient improvement on the North Star Ambulatory Assessme ...

LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 5,789,473 ordinary shares at a public offering price of $47.50 per share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 526,316 of its ordinary shares at the public offering price pe ...

Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).Results were presented at the International ATTR Amyloidosis Annual Meeting for Patients and Doctors. The results were simultaneously published in the New England Journal of Medicine.DataDeep, durable and consistent TTR reductions continue to be observed. Across ...

Key Takeaways QURE stock soared 247.7% after AMT-130 met primary and secondary endpoints in Huntington's disease study.High-dose AMT-130 slowed disease progression by 75% on cUHDRS and 60% on TFC at 36 months.AMT-130 showed dose-dependent benefits on motor and cognitive function with a manageable safety profile.Shares of uniQure N.V. (QURE) skyrocketed 247.7% on Wednesday after the company reported meeting key goals in the pivotal early to mid-stage study of its investigational gene therapy, AMT-130, for th ...

Ocugen (NasdaqCM:OCGN) 2025 Conference September 25, 2025 09:30 AM ET Company ParticipantsShankar Musunuri - CEO, Co-founder & Chairman of the BoardHuma Qamar - Chief Medical OfficerNoneWe're good to go. Okay. Good afternoon, and thanks for joining us to have a conversation with Shankar Moussunari, CEO, and Huma Kumar, CFO I mean, CMO of Ocugen. Ocugen is a biotech company focused on discovery, development, and commercializing novel gene and cell therapies. The company's proprietary gene therapy platform ha ...

CHARLESTOWN, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation investigational gene therapy intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 26th Annual Scientific Meeting of Neuromuscular Study Group (NMSG), September 26-28, 2025, in Stresa, Italy. Pr ...

LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $200 million underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends ...

Uniqure (QURE) stock soared nearly 300% on Wednesday after the Dutch biotechnology company announced a major breakthrough in Huntington’s disease. Investors are cheering QURE shares this morning because the Nasdaq-listed firm has secured new financing worth $175 million from Hercules Capital as well. More News from Barchart QURE stock is now trading roughly 460% above its year-to-date low in early April. www.barchart.com Why Did the Clinical Data Light a Fire Under QURE Stock? Uniqure shares are rall ...